02/14/2025
📊 The Changing Landscape of Glucose Monitoring: CGM vs. FGM
The U.S. glucose monitoring market is undergoing significant changes. Continuous glucose monitoring (CGM) systems, long considered the gold standard in diabetes management, were valued at over $6 billion in 2024 and are projected to grow at a 2% CAGR, surpassing $7 billion by 2031. However, a notable shift is happening in the market—flash glucose monitoring (FGM), a more affordable alternative, has grown 45% in the past three years and is expected to nearly double by 2031.
As diabetes rates continue to rise—driven in part by increasing obesity—the demand for glucose monitoring solutions is growing. CGMs offer real-time continuous tracking, providing critical insights for patients on intensive insulin therapy. Meanwhile, FGMs provide a cost-effective option for those who do not require constant monitoring, making diabetes management more accessible.
With market leaders like Dexcom, Abbott, and Medtronic competing in the CGM space and Abbott holding a dominant position in the FGM market, the future of glucose monitoring will be shaped by both technological advancements and pricing strategies. As CGM prices decrease with innovation slowdowns, could this impact the demand for FGM?
📖 Read our latest blog for a deep dive into these emerging trends, market projections, and what this means for the future of diabetes care:https://zurl.co/kbkLU
